effect date provisional 2001 3

substance identification.

=> s l40
L41 7 L40

=> d abs bib hitstr 1-7

L41 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AB The melanocortin-1 receptor (MC-1R) is a G-protein-coupled receptor involved in inflammation and skin pigmentation. Compound 2 is the first highly potent and selective MC-1R small-mol. agonist reported. Compound 2 showed efficacy in an acute model of inflammation, which has demonstrated the role of MC-1R in modulation of inflammation.
AN 2003:127461 CAPLUS
DN 138:297097
TI Discovery of Tyrosine-Based Potent and Selective Melanocortin-1 Receptor Small-Molecule Agonists with Anti-inflammatory Properties
AU Herpin, Timothy F.; Yu, Guixue; Carlson, Kenneth E.; Morton, George C.; Wu, Ximao; Kang, Liya; Tuerdi, Huji; Khanna, Ashish; Tokarski, John S.; Lawrence, R. Michael; Macor, John E.
CS Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543, USA
SO Journal of Medicinal Chemistry (2003), 46(7), 1123-1126
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT **508181-57-5**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tyrosine-based selective melanocortin-1 receptor agonists with anti-inflammatory properties)
RN 508181-57-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I

AB Compds. W-(CR6R7)yCH(G)(CR4R5)xCO-X(R1)CHR2(CHR3)r(CH2)sCO-E [X = N or CH; R1, R3 = H or alkyl; R2 = H, aryl, cycloalkyl, heteroaryl, heterocyclyl, (un)substituted alkyl or alkenyl; R1 together with R2 or R3 or R2 together with R3 form mono- or bicyclic aryl, cycloalkyl, heteroaryl, or heterocyclyl; E = (un)substituted pyrrolidino, piperidino, hexahydro-1-azepinyl, 1-piperazinyl, cyclopentyl, cyclohexyl, cycloheptyl, amino, (cyclo)alkylamino; R4-R6 = H, (un)substituted alkyl, amino, alkylamino, hydroxy, alkoxy, aryl, cycloalkyl, heteroaryl, or heterocyclyl; or CR4R5 or C6R7 is a spirocycloalkyl ring; r, s = 0 or 1; x = 0-4; y = 0-2; G = alkenyl, arylalkenyl, hydroxy, heteroaryl, cyano, functionalized alkyl or alkenyl, etc.; W = amino, alkylamino, hydroxy, alkoxy, carbamoyl, amidino, cycloalkyl, heteroaryl, heterocyclyl, etc.] were prepared as modulators of melanocortin receptors, particularly MC-1R and MC-4R. Thus, peptide I was prepared by a solution-phase peptide coupling/deprotection scheme.

AN 2002:695975 CAPLUS

DN 137:232913

TI Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors

IN Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R. Michael; Morton, George C.; Ruel, Rejean; Poindexter, Graham S.; Ruediger, Edward H.; Thibault, Carl

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2

DT Patent

LA English

application

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002070511	A1	20020912	WO 2002-US6479	20020302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437594	AA	20020912	CA 2002-2437594	20020302
EP 1363898	A1	20031126	EP 2002-723310	20020302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003092732	A1	20030515	US 2002-90582	20020304
US 2003096827	A1	20030522	US 2002-90288	20020304

	US 6713487	B2	20040330		
	US 2004229882	A1	20041118	US 2003-696761	20031029
PRAI	US 2001-273206P	P	20010302		
	US 2001-273291P	P	20010302		
	WO 2002-US6479	W	20020302		
	US 2002-90288	A3	20020304		

OS MARPAT 137:232913

IT **457893-85-5P 457902-24-8P 457902-27-1P**
457902-28-2P 457902-29-3P 457902-30-6P
457902-31-7P 457902-32-8P 457902-34-0P
457902-35-1P 457902-36-2P 457902-37-3P
457902-38-4P 457902-39-5P 457902-40-8P
457902-41-9P 457902-42-0P 457902-43-1P
457902-46-4P 457902-47-5P 457902-48-6P
457902-49-7P 457902-51-1P 457902-52-2P
457902-53-3P 457902-54-4P 457902-55-5P
457902-56-6P 457902-57-7P 457902-58-8P
457902-59-9P 457902-60-2P 457902-61-3P
457902-62-4P 457902-63-5P 457903-23-0P
457903-24-1P 457903-25-2P 457903-30-9P
457903-31-0P 457903-32-1P 457903-33-2P
457903-35-4P 457903-38-7P 457903-39-8P
457903-46-7P 457903-51-4P 457903-53-6P
457903-55-8P 457903-56-9P 457903-57-0P
457903-58-1P 457903-59-2P 457903-61-6P
457903-68-3P 457903-70-7P 457903-72-9P
457903-76-3P 457903-81-0P 457903-82-1P
457903-84-3P 457903-86-5P 457903-87-6P
457903-88-7P 457903-89-8P 457903-91-2P
457903-92-3P 457903-93-4P 457903-94-5P
457903-95-6P 457903-96-7P 457903-97-8P
457903-98-9P 457903-99-0P 457904-00-6P
457904-01-7P 457904-03-9P 457904-07-3P
457904-08-4P 457904-09-5P 457904-10-8P
457904-11-9P 457904-12-0P 457904-13-1P
457904-14-2P 457904-15-3P 457904-16-4P
457904-17-5P 457904-18-6P 457904-19-7P
457904-20-0P 457904-21-1P 457904-22-2P
457904-23-3P 457904-24-4P 457904-25-5P
457904-26-6P 457904-27-7P 457904-28-8P
457904-32-4P 457904-33-5P 457904-34-6P
457904-35-7P 457904-36-8P 457904-37-9P
457904-38-0P 457904-39-1P 457904-40-4P
457904-41-5P 457904-43-7P 457904-44-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides for pharmaceutical use as modulators of melanocortin receptors)

RN 457893-85-5 CAPLUS

CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-24-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-[(4-chlorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-27-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[3-methyl-1-[[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]carbonyl]butyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-28-2 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]carbonyl]pentyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-29-3 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]-1-(2-thienylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-30-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(4-nitrophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-31-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-32-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]carbonyl]-3-phenylpropyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-34-0 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-(1-naphthalenylmethyl)-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-35-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-36-2 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(4-iodophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-37-3 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-(benzo[b]thien-3-ylmethyl)-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-38-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-(cyclohexylmethyl)-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-39-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(3,4-dichlorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-40-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-([1,1'-biphenyl]-4-

ylmethyl)-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-41-9 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-(diphenylmethyl)-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-42-0 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(4-benzoylphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-43-1 CAPLUS

CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(4-bromophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-46-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(3-chlorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-47-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(3,4-difluorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-48-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(2-fluorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-49-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(3-fluorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-51-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(3,5-difluorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-52-2 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(2-chlorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-53-3 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]-1-[[4-(2-propenyloxy)phenyl]methyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-54-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]-1-(3-pyridinylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-55-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]-1-(4-thiazolylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-56-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]-1-(4-pyridinylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-57-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(3-cyanophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-58-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-methyl-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-59-9 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(4-cyanophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-60-2 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(4-methylphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-

, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-61-3 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]carbonyl]-4-phenyl-3-butenyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 457902-62-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[1-[(3,4-dimethoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457902-63-5 CAPLUS

CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[3-cyclohexyl-1-[[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]carbonyl]propyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-23-0 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[[3-(2-chlorophenyl)-1-oxopropyl]amino]-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-24-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[(cyclopentylacetyl)amino]-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-25-2 CAPLUS
CN 3-Pyridinepropanamide, N-[(1S)-1-(1H-imidazol-4-ylmethyl)-2-[[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-30-9 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(1-oxobutyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-31-0 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(3-methyl-1-oxobutyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-32-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[[(2-methoxyphenyl)acetyl]amino]-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-33-2 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(1-oxopentyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-35-4 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(phenylacetyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-38-7 CAPLUS
CN Pentanoic acid, 5-[[(1S)-1-(1H-imidazol-4-ylmethyl)-2-[[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]amino]-2-oxoethyl]amino]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-39-8 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(1-oxo-3-phenyl-2-propenyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 457903-46-7 CAPLUS
CN Hexanoic acid, 6-[[(1S)-1-(1H-imidazol-4-ylmethyl)-2-[[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]amino]-2-oxoethyl]amino]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-51-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[(2,2-dimethyl-1-oxopropyl)amino]-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-53-6 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(2-methyl-1-oxopropyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-55-8 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[[3-(2-methoxyphenyl)-1-oxopropyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-56-9 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[[3-(4-methoxyphenyl)-1-oxopropyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-57-0 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[[3-(3-methoxyphenyl)-1-oxopropyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-58-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[[3-(4-chlorophenyl)-1-oxopropyl]amino]-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-59-2 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(1-oxo-4-phenylbutyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-61-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[(cyclohexylacetyl)amino]-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-68-3 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(1-oxopropyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-70-7 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[[(phenylmethoxy)acetyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-72-9 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[(2-furanylacetyl)amino]-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-76-3 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(phenoxyacetyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-81-0 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-82-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-84-3 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-(1-piperidinyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-86-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(4-hydroxy-4-phenyl-1-piperidinyl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-87-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-88-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-89-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[1,4'-bipiperidin]-1'-yl-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-91-2 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-(octahydro-2(1H)-isoquinolinyl)-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-92-3 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-pyrrolidinyl)-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-93-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-94-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-[(acetylamino)methyl]-4-phenyl-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-95-6 CAPLUS
CN 4-Piperidinecarboxamide, 1-[(2S)-2-[[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]amino]-3-(4-methoxyphenyl)-1-oxopropyl]-4-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-96-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-(3-methyl-3-phenyl-1-piperidinyl)-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-97-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-[4-(2-methoxyphenyl)-1-piperidinyl]-2-oxoethyl]-,

(αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-98-9 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457903-99-0 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-[4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-1-piperidinyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-00-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(3,4-dihydro-4-phenyl-2(1H)-isoquinolinyl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-01-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(3,4-dihydro-2(1H)-isoquinolinyl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-03-9 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(3,4-dihydro-3-oxospiro[isoquinoline-1(2H),4'-piperidin]-1'-yl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-07-3 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(2,3-dihydro-3-oxospiro[1H-isoindole-1,4'-piperidin]-1'-yl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-08-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-09-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-[4-(1-naphthalenyl)-1-piperidinyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-10-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-11-9 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-12-0 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-13-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-spiro[1H-indene-1,4'-piperidin]-1'-ylethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-14-2 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-15-3 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(2,3-dihydro-6-methoxy-1H-inden-1-yl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-16-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(4-cyclohexyl-1-piperidinyl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-17-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(2,3-dihydro-6-methoxy-3,3-dimethyl-1H-inden-1-yl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-18-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-[4-(1-methylethyl)-1-piperidinyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-19-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(4-phenyl-2-oxazolyl)-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-20-0 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(1,1-dimethylethyl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-21-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(3',4'-dihydro-1'-methyl-4'-oxospiro[piperidine-4,2'(1'H)-quinazolin]-1-yl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-22-2 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(2,3-dihydro-1H-inden-1-yl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-23-3 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-[hydroxy(3-methoxyphenyl)methyl]-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-24-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(1,3-benzodioxol-4-ylmethyl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-25-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-[4-(5-methyl-1H-imidazol-4-yl)-1-piperidinyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-26-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(1,2-benzisothiazol-3-ylamino)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-27-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-(4-thieno[3,2-c]pyridin-4-yl-1-piperidinyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-28-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-[4-(3-methylthieno[3,2-c]pyridin-4-yl)-1-piperidinyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-32-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[3-(1H-indol-2-yl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-33-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(4,4-diphenyl-1-piperidinyl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-34-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-(3-phenylspiro[1H-indene-1,4'-piperidin]-1'-yl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-35-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(2,3-dihydro-3-phenylspiro[1H-indene-1,4'-piperidin]-1'-yl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-36-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-[(1-oxopropyl)phenylamino]-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-37-9 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(3,4-dihydrospiro[2H-1-benzopyran-2,4'-piperidin]-1'-yl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-38-0 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(1,4-cyclohexadien-1-ylmethyl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-39-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-40-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(diphenylmethyl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-41-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-43-7 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-(1,2-dihydro-6-methyl-2-oxospiro[4H-3,1-benzoxazine-4,4'-piperidin]-1'-yl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457904-44-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1S)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AB Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is described for modulating levels of cyclic adenosine 3',5' monophosphate (cAMP) in a mammal. The inventive co-administration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatitis, psoriasis, migraine,

Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury.

AN 2002:695727 CAPLUS
DN 137:226646
TI Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
IN Macor, John E.; Carlson, Kenneth E.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002069905	A2	20020912	WO 2002-US6805	20020304
	WO 2002069905	A3	20031009		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2439691	AA	20020912	CA 2002-2439691	20020304
	US 2003069169	A1	20030410	US 2002-90258	20020304
	EP 1370211	A2	20031217	EP 2002-713772	20020304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004229882	A1	20041118	US 2003-696761	20031029
PRAI	US 2001-273206P	P	20010302		
	US 2001-273291P	P	20010302		
	US 2001-289719P	P	20010509		
	US 2002-90288	A3	20020304		
	WO 2002-US6805	W	20020304		

OS MARPAT 137:226646
IT **457893-85-5P 457894-19-8P 457894-20-1P 457894-23-4P 457894-25-6P 457894-29-0P 457894-31-4P 457894-32-5P 457894-51-8P 457894-52-9P 457894-53-0P 457894-56-3P 457895-21-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-associated disorders)
RN 457893-85-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-19-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-3-methyl-1-[[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]carbonyl]butyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-20-1 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-23-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-[(4-benzoylphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-25-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-[(3-fluorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-29-0 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]-1-(4-thiazolylmethyl)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-31-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-[[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]carbonyl]-4-phenyl-3-butenyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 457894-32-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-[(4-chlorophenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-51-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-(4-methyl-4-phenyl-1-piperidinyl)-2-oxoethyl]-,

(αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-52-9 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-2-[4-(1,1-dimethylethyl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-53-0 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-2-(3',4'-dihydro-1'-methyl-4'-oxospiro[piperidine-4,2'(1'H)-quinazolin]-1-yl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-56-3 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-2-(1,2-dihydro-6-methyl-2-oxospiro[4H-3,1-benzoxazine-4,4'-piperidin]-1'-yl)-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457895-21-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-(acetylamino)-N-[(1R)-1-methyl-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II

AB RCOCR1R1aNR2aCOCR4aR4bNR4cCOCR4aR4bNR4R5 [R = e.g., 1-azacycloalkyl group I; R1 = alkyl, (hetero)aryl(alkyl), etc.; R1a,R2a = H or alkyl; R3 = (cyclo)alkyl, (hetero)aryl(alkyl), etc.; R4,R4c,R5 = H or (un)substituted alkyl; NR4R5 = heterocyclyl; R4a,R4b = H, (heteroaryl)alkyl, Ph, etc.; X = H, cyano, acylamino(alkyl), etc.; Y = H, alkyl, aryl(alkyl), etc.; Z = bond, CH2, CH2CH2] were prepared as growth hormone release stimulants (no data). Thus, Boc-D-TrpOH was amidated by RH (R = piperidino group II)(preparation given) and the deprotected product condensed with BocSarSarOH (preparation given) to give, after deprotection, (R)-RCOCHR1NHCOCH2NMeCOCH2NHMe (R = II, R1 = 3-indolylmethyl).

AN 1998:590736 CAPLUS

DN 129:231016

TI Preparation of tryptophan piperidides and analogs as growth hormone release stimulants

IN Chakravarty, Prasun K.; Chen, Meng H.; Nargund, Ravi; Patchett, Arthur A.; Tata, James R.; Wu, Mu Tsu; Yang, Lihu

PA Merck and Co., Inc., USA

SO U.S., 57 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5804578	A	19980908	US 1997-828606	19970331
PRAI	US 1997-828606		19970331		

OS MARPAT 129:231016

IT **197900-69-9P 197900-70-2P 197900-71-3P**
197900-72-4P 197900-73-5P 197901-40-9P
197901-41-0P 197901-42-1P 197901-43-2P
197901-44-3P 197901-45-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tryptophan piperidides and analogs as growth hormone release stimulants)

RN 197900-69-9 CAPLUS

CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 197900-70-2 CAPLUS
CN L-Histidinamide, D-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 HCl

RN 197900-71-3 CAPLUS
CN L-Histidinamide, D-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 197900-72-4 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 197900-73-5 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-1-[[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]carbonyl]-4-phenylbutyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 197901-40-9 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-41-0 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[3-[(dimethylamino)carbonyl]-2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-42-1 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-1-(1H-indol-3-ylmethyl)-2-[3-(5-methyl-1,3,4-oxadiazol-2-yl)-4-phenyl-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-43-2 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[3-[(ethylamino)carbonyl]-4-phenyl-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-44-3 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-45-4 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-[(ethylamino)carbonyl]-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **212773-89-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tryptophan piperidides and analogs as growth hormone release stimulants)
RN 212773-89-2 CAPLUS
CN L-Histidinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

AB Bombesin receptor antagonists are possible therapeutic agents due to their ability to act as inhibitors of cellular proliferation. On the basis of our hypothesis on the mechanism of action of gastrin associating an activating enzyme system to the receptor and on the results reported in the literature, we have synthesized bombesin analogs which have been modified in the C-terminal Leu13-Leu14 amide part. We have shown that modification in the C-terminal part of the bombesin strongly affected the biol. activity in rat pancreatic acini. The most potent compound which is described here, H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-ψ(CH2)Leu-NH2, was able to recognize the bombesin receptor on rat pancreatic acini (Ki 4.3 nM) and antagonized the bombesin stimulated amylase secretion (Ki 7.7 nM).

AN 1997:752569 CAPLUS

DN 128:84030

TI Syntheses and biological activities of bombesin analogs modified in the C-terminal dipeptide part

AU Llinares, M.; Devin, C.; Azay, J.; Berge, G.; Fehrentz, J. A.; Martinez, J.

CS Laboratoire des Amino-acides, Peptides et Proteines (LAPP), CNRS - Faculte de Pharmacie, ESA 5075, Universites Montpellier I and II, Montpellier, 34060, Fr.

SO European Journal of Medicinal Chemistry (1997), 32(10), 767-780
CODEN: EJMCA5; ISSN: 0223-5234

PB Editions Scientifiques et Medicales Elsevier

DT Journal

LA English

IT **200949-12-8P 200949-13-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and receptor antagonistic activities of bombesin analogs modified in C-terminal dipeptide part)

RN 200949-12-8 CAPLUS

CN 3-Isoquinolinecarboxamide, D-phenylalanyl-L-glutaminyl-L-tryptophyl-L-

alanyl-L-valylglycyl-L-histidyl-L-leucyl-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 200949-13-9 CAPLUS
CN 3-Isoquinolinecarboxamide, D-phenylalanyl-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **200949-75-3P 200949-78-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and receptor antagonistic activities of bombesin analogs modified in C-terminal dipeptide part)

RN 200949-75-3 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-D-phenylalanyl-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 200949-78-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-D-phenylalanyl-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I









II III

AB Title compds. I [B = Q1, Q2; R1 = (un)substituted C1-10 alkyl, aryl, aryl-C1-6 alkyl, heteroaryl, heteroaryl-C1-6 alkyl, C3-6 cycloalkyl-C1-6 alkyl, etc; R1a = H, C1-4 alkyl; R2a = H, C1-6 alkyl; R3 = H, C1-10 alkyl, (un)substituted C3-7 cycloalkyl, (CH2)rR, R = Ph, thienyl, benzimidazolyl, quinolinyl, naphthyl, indolyl; R3a, R3b = independently H, Ph, OPh, halophenyl, C1-6 alkyl, halo, OR2, methylenedioxy S(O)mR2, CF3, OCF3, NO2, NR22, NR2COR2, CO2R2, CONR22, SO2NR22, NR2SO2-aryl, NR2SO2R2, R2 = H, CH2Ph, (un)substituted C1-6 alkyl, C3-6 cycloalkyl; R4, R5 = independently H, (un)substituted C1-6 alkyl or R4R5 form a heterocyclic ring; R4a, R4b = independently H, CF3, Ph, (un)substituted C1-6 alkyl, or may form ring with R4 or R4c; R4c = H, (un)substituted C1-6 alkyl; X, Y = H, variable N-substituted alkyl, etc; D = NR7, S(O)m, CO, CHR7; R7 = R2, OR2, COR2, (CH2)s-aryl, CO(CH2)s-aryl, SO2R2, SO2(CH2)s-aryl, CONR22, CONR2(CH2)s-aryl, CO2R2, tetrazolyl, SO2NR2-aryl, SO2NR22; m = 0-2; n = 0-2, ; r = 0-3; s = 0-4; p, q undefined] are prepared as compds. that promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiol. or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compns. containing such compds. as the active ingredient thereof are also disclosed. Thus, sequential peptide coupling of substituted piperidine II (preparation given) with Boc-D-Trp-OH and Boc-Sar-Sar-OH gave desired tripeptidyl piperidine III as its HCl salt.

AN 1997:679061 CAPLUS
DN 127:331748

TI Preparation of peptidyl piperidines, pyrrolidines, and hexahydro-1H-azepines as growth hormone release promoters

IN Chakravarty, Prasun K.; Chen, Meng H.; Nargund, Ravi; Patchett, Arthur A.; Tata, James R.; Wu, Mu Tsu; Yang, Lihu
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9736873	A1	19971009	WO 1997-US5378	19970331
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9727222	A1	19971022	AU 1997-27222	19970331
PRAI	US 1996-14797P	P	19960403		
	GB 1996-9664	A	19960509		
	WO 1997-US5378	W	19970331		

OS MARPAT 127:331748
IT **197900-69-9P 197900-70-2P 197900-71-3P**
197900-72-4P 197900-73-5P 197901-40-9P
197901-41-0P 197901-42-1P 197901-43-2P
197901-44-3P 197901-45-4P 197901-46-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptidyl piperidines, pyrrolidines, and hexahydroazepines as growth hormone release promoters)
RN 197900-69-9 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 197900-70-2 CAPLUS
CN L-Histidinamide, D-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 197900-71-3 CAPLUS
CN L-Histidinamide, D-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 197900-72-4 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 197900-73-5 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-1-[[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]carbonyl]-4-phenylbutyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 197901-40-9 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-41-0 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[3-[(dimethylamino)carbonyl]-2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-42-1 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-1-(1H-indol-3-ylmethyl)-2-[3-(5-methyl-1,3,4-oxadiazol-2-yl)-4-phenyl-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-43-2 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[3-[(ethylamino)carbonyl]-4-phenyl-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-44-3 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-45-4 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-[(ethylamino)carbonyl]-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-46-5 CAPLUS
CN L-Histidinamide, L-alanyl-N-[(1R)-2-(1,1-dioxidospiro[benzo[b]thiophene-3(2H),4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AB A-B-C-D-(E)p [p = 0, 1; A = H, R1(CH2)qXr(CH2)sCO; q = 0-5; r = 0,1; s = 0-5; R1 = H, imidazolyl, guanidino, piperazino, morpholino, piperidino, etc.; X = NH, CH2, CH:CH, phenylene, cyclohexylene, naphthylene, thienylene, (substituted) methylene, etc.; B = GtHu; u, t = 0, 1; G, H = D- or L-amino acids, including unnatural amino acids; C, D = defined D-amino acids; E = NHCHR10(CH2)vR9; v = 0-8; R9 = H, imidazolyl,

guanidino, piperazino, morpholino, piperidino, etc.; R10 = H, CO2H, CH2OH, etc.; amide bonds may be modified], were prepared Thus, H-Ala-Phe-D-2Nal-D-Phe-Lys-NH2 (2Nal = 2-naphthylalanyl) (prepared by solid phase synthesis) showed EC50 = 2 nM for stimulation of growth hormone secretion from rat pituitary cells.

AN 1995:951186 CAPLUS
DN 124:9462
TI Preparation of peptides with growth hormone releasing properties.
IN Johansen, Nils Langeland; Lau, Jesper; Madsen, Kjeld; Lundt, Behrend Friedrich; Thoegersen, Henning; Hansen, Birgit Sehested; Peschke, Bernd
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9517423	A1	19950629	WO 1994-DK485	19941222
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9410261	A	19950623	ZA 1994-10261	19941222
	CA 2179597	AA	19950629	CA 1994-2179597	19941222
	AU 9512724	A1	19950710	AU 1995-12724	19941222
	AU 689181	B2	19980326		
	HU 73497	A2	19960828	HU 1995-1947	19941222
	EP 736039	A1	19961009	EP 1995-903774	19941222
	EP 736039	B1	20001025		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1138335	A	19961218	CN 1994-194590	19941222
	CN 1052731	B	20000524		
	JP 09507217	T2	19970722	JP 1995-517109	19941222
	JP 3181918	B2	20010703		
	BR 9408377	A	19970819	BR 1994-8377	19941222
	RO 115635	B1	20000428	RO 1996-1293	19941222
	IL 112112	A1	20000629	IL 1994-112112	19941222
	AT 197158	E	20001115	AT 1995-903774	19941222
	ES 2153469	T3	20010301	ES 1995-903774	19941222
	PT 736039	T	20010430	PT 1995-903774	19941222
	PL 181280	B1	20010731	PL 1994-315113	19941222
	SK 281963	B6	20010911	SK 1996-820	19941222
	CZ 293113	B6	20040218	CZ 1996-1834	19941222
	TW 438811	B	20010607	TW 1995-84100274	19950113
	US 5767085	A	19980616	US 1995-448623	19950606
	FI 9602584	A	19960620	FI 1996-2584	19960620
	NO 9602665	A	19960823	NO 1996-2665	19960621
	GR 3035150	T3	20010430	GR 2000-402838	20001227
PRAI	DK 1993-1439	A	19931223		
	DK 1994-121	A	19940128		
	DK 1994-1191	A	19941014		
	WO 1994-DK485	W	19941222		

OS MARPAT 124:9462
IT **170851-25-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides with growth hormone releasing properties)

RN 170851-25-9 CAPLUS

CN L-Lysinamide, L-alanyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 170851-24-8
CMF C38 H47 N9 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.20	1934.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.90	-27.30

12/23/04

FILE 'REGISTRY' ENTERED AT 14:08:28 ON 23 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 DEC 2004 HIGHEST RN 800413-66-5
DICTIONARY FILE UPDATES: 21 DEC 2004 HIGHEST RN 800413-66-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10696761.str

L42 STRUCTURE UPLOADED

=> d l42
L42 HAS NO ANSWERS
L42 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l42
SAMPLE SEARCH INITIATED 14:08:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 0 TO 0

L43 0 SEA SSS SAM L42

=> s l42 ful
FULL SEARCH INITIATED 14:08:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 111 TO ITERATE

100.0% PROCESSED 111 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

12/23/04

L44 6 SEA SSS FUL L42

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	2090.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-27.30

FILE 'CAPLUS' ENTERED AT 14:08:59 ON 23 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Dec 2004 VOL 141 ISS 26
FILE LAST UPDATED: 22 Dec 2004 (20041222/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l44
L45 3 L44

=> d abs bib hitstr 1-3

L45 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I

AB Compds. W-(CR6R7)yCH(G)(CR4R5)xCO-X(R1)CHR2(CHR3)r(CH2)sCO-E [X = N or CH; R1, R3 = H or alkyl; R2 = H, aryl, cycloalkyl, heteroaryl, heterocyclyl, (un)substituted alkyl or alkenyl; R1 together with R2 or R3 or R2 together with R3 form mono- or bicyclic aryl, cycloalkyl, heteroaryl, or heterocyclyl; E = (un)substituted pyrrolidino, piperidino, hexahydro-1-azepinyl, 1-piperazinyl, cyclopentyl, cyclohexyl, cycloheptyl, amino, (cyclo)alkylamino; R4-R6 = H, (un)substituted alkyl, amino,

alkylamino, hydroxy, alkoxy, aryl, cycloalkyl, heteroaryl, or heterocyclyl; or CR4R5 or C6R7 is a spirocycloalkyl ring; r, s = 0 or 1; x = 0-4; y = 0-2; G = alkenyl, arylalkenyl, hydroxy, heteroaryl, cyano, functionalized alkyl or alkenyl, etc.; W = amino, alkylamino, hydroxy, alkoxy, carbamoyl, amidino, cycloalkyl, heteroaryl, heterocyclyl, etc.] were prepared as modulators of melanocortin receptors, particularly MC-1R and MC-4R. Thus, peptide I was prepared by a solution-phase peptide coupling/deprotection scheme.

AN 2002:695975 CAPLUS
DN 137:232913
TI Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors
IN Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R. Michael; Morton, George C.; Ruel, Rejean; Poindexter, Graham S.; Ruediger, Edward H.; Thibault, Carl
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070511	A1	20020912	WO 2002-US6479	20020302
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2437594	AA	20020912	CA 2002-2437594	20020302
	EP 1363898	A1	20031126	EP 2002-723310	20020302
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003092732	A1	20030515	US 2002-90582	20020304
	US 2003096827	A1	20030522	US 2002-90288	20020304
	US 6713487	B2	20040330		
	US 2004229882	A1	20041118	US 2003-696761	20031029
PRAI	US 2001-273206P	P	20010302		
	US 2001-273291P	P	20010302		
	WO 2002-US6479	W	20020302		
	US 2002-90288	A3	20020304		

OS MARPAT 137:232913
IT **457894-34-7P 457894-35-8P 457894-36-9P 457894-37-0P 457894-38-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides for pharmaceutical use as modulators of melanocortin receptors)
RN 457894-34-7 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(methylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-35-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[(ethylsulfonyl)amino]-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-36-9 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(propylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-37-0 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(phenylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-38-1 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[[(phenylmethyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L45 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AB Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is described for modulating levels of cyclic adenosine 3',5' monophosphate (cAMP) in a mammal. The inventive co-administration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatitis, psoriasis, migraine, Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury.

12/23/04

AN 2002:695727 CAPLUS
DN 137:226646
TI Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
IN Macor, John E.; Carlson, Kenneth E.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002069905	A2	20020912	WO 2002-US6805	20020304
	WO 2002069905	A3	20031009		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2439691	AA	20020912	CA 2002-2439691	20020304
	US 2003069169	A1	20030410	US 2002-90258	20020304
	EP 1370211	A2	20031217	EP 2002-713772	20020304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004229882	A1	20041118	US 2003-696761	20031029
PRAI	US 2001-273206P	P	20010302		
	US 2001-273291P	P	20010302		
	US 2001-289719P	P	20010509		
	US 2002-90288	A3	20020304		
	WO 2002-US6805	W	20020304		

OS MARPAT 137:226646
IT **457894-34-7P 457894-35-8P 457894-36-9P 457894-37-0P 457894-38-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-associated disorders)
RN 457894-34-7 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(methylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-35-8 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[(ethylsulfonyl)amino]-N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-36-9 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(propylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-37-0 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(phenylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457894-38-1 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[[(phenylmethyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L45 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AB Several new analogs of the known thrombin inhibitor NAPAP were synthesized, in which the P2 glycine residue was substituted by natural and unnatural amino acids. The thrombin inhibitory potency was comparable to that of NAPAP. Several of the compds. had inhibition consts. lower than 10nM and a very high selectivity compared to trypsin, factor χa and plasmin. In addition, analogs were prepared by alkylation of the Nα-atom of the 4-amidinophenylalanine in P1 position, which showed a more than 10-fold lower thrombin inhibition. Furthermore, aza-glycine was introduced instead of P2 glycine. For most of the inhibitors similar fast elimination rates were seen in rats after i.v. dosing, as found previously for NAPAP. Only some compds., which contained a second basic group showed a slightly decreased cumulative biliary clearance.
AN 2001:629886 CAPLUS

12/23/04

DN 136:174
TI Structure-activity relationships of new NAPAP-analogs
AU Steinmetzer, Torsten; Schweinitz, Andrea; Kunzel, Sebastian; Wikstrom, Peter; Hauptmann, Jorg; Sturzebecher, Jorg
CS Inst. of Biochemistry & Biophysics, Friedrich Schiller University, Jena, D-07743, Germany
SO Journal of Enzyme Inhibition (2001), 16(3), 241-249
CODEN: ENINEG; ISSN: 8755-5093
PB Harwood Academic Publishers
DT Journal
LA English
IT **376390-23-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-activity relationships of NAPAP-analogs as thrombin inhibitors)
RN 376390-23-7 CAPLUS
CN 1H-Imidazole-4-propanamide, N-[1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-α-[(2-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.72	2104.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.10	-29.40

FILE 'STNGUIDE' ENTERED AT 14:09:21 ON 23 DEC 2004

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 17, 2004 (20041217/UP).

100.0% PROCESSED 3314 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L50 0 SEA SSS FUL L49

=> file uspatall

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	2416.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-29.40

FILE 'USPATFULL' ENTERED AT 14:15:21 ON 23 DEC 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:15:21 ON 23 DEC 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l45
L51 5 L45

=> d abs bib fhitstr 1-5

L51 ANSWER 1 OF 5 USPATFULL on STN
AB Compounds having the formula (I), ##STR1##

G is a novel side chain selected from C.sub.2-6alkenyl, A.sub.3-aryl, --OR.sub.18, heteroaryl, A.sub.1-cyano, A.sub.2--OR.sub.17, A.sub.1--C(.dbd.O)R.sub.18, A.sub.1--CO.sub.2R.sub.18, A.sub.1--C(.dbd.O)NR.sub.18R.sub.19, A.sub.1--OC(.dbd.O)R.sub.18, A.sub.1--NR.sub.18C(.dbd.O)R.sub.19, A.sub.1--OC(.dbd.O)NR.sub.18R.sub.19, A.sub.1--NR.sub.18CO.sub.2R.sub.19, A.sub.1--NR.sub.18SO.sub.2R.sub.17, A.sub.1--SO.sub.2R.sub.17, A.sub.1--NR.sub.20C(.dbd.O)NR.sub.18R.sub.19, and A.sub.1--SR.sub.18; or when y is 0 or when W is not NHR.sub.22, G may be A.sub.1-heterocyclo, wherein Al is a bond, C.sub.1-6alkylene or C.sub.2-alkenylene, A.sub.2 is C.sub.1-6alkylene or C.sub.2-6alkenylene, and A.sub.3 is C.sub.2-6alkenylene; W is selected from --NR.sub.21R.sub.22, --OR.sub.23, --NR.sub.21C(.dbd.O)R.sub.24, --NR.sub.21CO.sub.2R.sub.24, amidino, guanidino, or a heteroaryl, heterocyclo or C.sub.3-7cycloalkyl as defined in the specification, and X and R.sub.1 through R.sub.24 are as defined in the specification, are effective as modulators of melanocortin-receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:292793 USPATFULL
TI Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
IN Yu, Guixue, Lawrenceville, NJ, UNITED STATES
Macor, John, Guilford, CT, UNITED STATES
Herpin, Timothy, Princeton, NJ, UNITED STATES
Lawrence, R. Michael, Yardley, PA, UNITED STATES
Morton, George C., Collegeville, PA, UNITED STATES
Ruel, Rejean, Saint-Lambert, CANADA
Poindexter, Graham S., Old Saybrook, CT, UNITED STATES
Ruediger, Edward H., Greenfield Park, CANADA

Thibault, Carl, Mascouche, CANADA
PI US 2004229882 A1 20041118
AI US 2003-696761 A1 20031029 (10)
RLI Division of Ser. No. US 2002-90288, filed on 4 Mar 2002, GRANTED, Pat. No. US 6713487
PRAI US 2001-273206P 20010302 (60)
US 2001-273291P 20010302 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2500
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **457894-34-7P**
(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-associated disorders)
RN 457894-34-7 USPATFULL
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(methylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L51 ANSWER 2 OF 5 USPATFULL on STN
AB Compounds having the formula (I), ##STR1##

NR.sub.11R.sub.12; G is a novel side chain selected from C.sub.2-6alkenyl, A.sub.3-aryl, --OR.sub.18, heteroaryl, A.sub.1-cyano, A.sub.2--OR.sub.17, A.sub.1--C(.dbd.O)R.sub.18, A.sub.1--CO.sub.2R.sub.18, A.sub.1--C(.dbd.O)NR.sub.18R.sub.19, A.sub.1--OC(.dbd.O)R.sub.18, A.sub.1--NR.sub.18C(.dbd.O)R.sub.19, A.sub.1--OC(.dbd.O)NR.sub.18R.sub.19, A.sub.1--NR.sub.18CO.sub.2R.sub.19, A.sub.1--NR.sub.18SO.sub.2R.sub.17, A.sub.1--SO.sub.2R.sub.17, A.sub.1--NR.sub.20C(.dbd.O)NR.sub.18R.sub.19, and A.sub.1--SR.sub.18; or when y is 0 or when W is not NHR.sub.22, G may be A.sub.1-heterocyclo, wherein A.sub.1 is a bond, C.sub.1-6alkylene or C.sub.2-alkenylene, A.sub.2 is C.sub.1-6alkylene or C.sub.2-6alkenylene, and A.sub.3 is C.sub.2-6alkenylene; W is selected from --NR.sub.21R.sub.22, --OR.sub.23, --NR.sub.21C(.dbd.O)R.sub.24, --NR.sub.21CO.sub.2R.sub.24, amidino, guanidino, or a heteroaryl,

heterocyclo or C.sub.3-7cycloalkyl as defined in the specification, and X and R.sub.1 through R.sub.24 are as defined in the specification, are effective as modulators of melanocortin-receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:140985 USPATFULL
TI Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
IN Yu, Guixue, Lawrenceville, NJ, UNITED STATES
Macor, John, Guilford, CT, UNITED STATES
Herpin, Timothy, Princeton, NJ, UNITED STATES
Lawrence, R. Michael, Yardley, PA, UNITED STATES
Morton, George C., Collegeville, PA, UNITED STATES
Ruel, Rejean, Saint-Lambert, CANADA
Poindexter, Graham S., Old Saybrook, CT, UNITED STATES
Ruediger, Edward H., Greenfield Park, CANADA
Thibault, Carl, Mascouche, CANADA
PI US 2003096827 A1 20030522
US 6713487 B2 20040330
AI US 2002-90288 A1 20020304 (10)
PRAI US 2001-273206P 20010302 (60)
US 2001-273291P 20010302 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **457894-34-7P**
(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-associated disorders)
RN 457894-34-7 USPATFULL
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(methylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L51 ANSWER 3 OF 5 USPATFULL on STN

AB Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, ##STR1##

in which E is

X is N or CH, W is --NR.sub.16R.sub.17, --NR.sub.16C(.dbd.O)R.sub.22, --NR.sub.16CO.sub.2R.sub.22, --OR.sub.23, or a heteroaryl or heterocyclo group as defined in the specification, and R.sub.1 through R.sub.12, R.sub.16, R.sub.17, R.sub.22, R.sub.23, x, y, and z are as defined in the specification, are useful as modulaters of melanocortin receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:134643 USPATFULL

TI Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

IN Yu, Guixue, Lawrenceville, NJ, UNITED STATES
Macor, John, Guilford, CT, UNITED STATES
Herpin, Timothy, Princeton, NJ, UNITED STATES
Lawrence, R. Michael, Yardley, PA, UNITED STATES
Morton, George C., Collegeville, PA, UNITED STATES
Ruel, Rejean, Saint-Lambert, CANADA
Poindexter, Graham S., Old Saybrook, CT, UNITED STATES
Ruediger, Edward H., Greenfield Park, CANADA
Thibault, Carl, Mascouche, CANADA

PI US 2003092732 A1 20030515

AI US 2002-90582 A1 20020304 (10)

PRAI US 2001-273206P 20010302 (60)
US 2001-273291P 20010302 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2878

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **457894-34-7P**
(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-associated disorders)

RN 457894-34-7 USPATFULL

CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(methylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L51 ANSWER 4 OF 5 USPATFULL on STN

AB Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is described for modulating levels of cyclic adenoise 3',5' monophosphate (cAMP) in a mammal. The inventive co-administration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatis, psoriasis, migraine, Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:100059 USPATFULL

TI Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders

IN Macor, John E., Guilford, CT, UNITED STATES
Carlson, Kenneth E., West Windsor, NJ, UNITED STATES

PI US 2003069169 A1 20030410

AI US 2002-90258 A1 20020304 (10)

PRAI US 2001-273206P 20010302 (60)
US 2001-273291P 20010302 (60)
US 2001-289719P 20010509 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 2497

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **457894-34-7P**
(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-associated disorders)

RN 457894-34-7 USPATFULL

CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(methylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L51 ANSWER 5 OF 5 USPAT2 on STN
AB Compounds having the formula (I), ##STR1##

--NR.sub.11R.sub.12; G is a novel side chain selected from C.sub.2-6alkenyl, A.sub.3-aryl, --OR.sub.18, heteroaryl, A.sub.1-cyano, A.sub.2--OR.sub.17, A.sub.1--C(.dbd.O)R.sub.18, A.sub.1--CO.sub.2R.sub.18, A.sub.1--C(.dbd.O)NR.sub.18R.sub.19, A.sub.1--OC(.dbd.O)R.sub.18, A.sub.1--NR.sub.18C(.dbd.O)R.sub.19, A.sub.1--OC(.dbd.O)NR.sub.18R.sub.19, A.sub.1--NR.sub.18CO.sub.2R.sub.19, A.sub.1--NR.sub.18SO.sub.2R.sub.17, A.sub.1--SO.sub.2R.sub.17, A.sub.1--NR.sub.20C(.dbd.O)NR.sub.18R.sub.19, and A.sub.1--SR.sub.18; or when y is 0 or when W is not NHR.sub.22, G may be A.sub.1-heterocyclo, wherein A.sub.1 is a bond, C.sub.1-6alkylene or C.sub.2-alkenylene, A.sub.2 is C.sub.1-6alkylene or C.sub.2-6alkenylene, and A.sub.3 is C.sub.2-6alkenylene; W is selected from --NR.sub.21R.sub.22, --OR.sub.23, --NR.sub.21C(.dbd.O)R.sub.24, --NR.sub.21CO.sub.2R.sub.24, amidino, guanidino, or a heteroaryl, heterocyclo or C.sub.3-7cycloalkyl as defined in the specification, and X and R.sub.1 through R.sub.24 are as defined in the specification, are effective as modulators of melanocortin-receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:140985 USPAT2
TI Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
IN Yu, Guixue, Lawrenceville, NJ, United States
Macor, John, Guilford, CT, United States
Herpin, Timothy, Princeton, NJ, United States
Lawrence, R. Michael, Yardley, PA, United States
Morton, George C., Collegeville, PA, United States
Ruel, Rejean, Saint-Lambert, CANADA
Poindexter, Graham S., Old Saybrook, CT, United States
Ruediger, Edward H., Greenfield Park, CANADA
Thibault, Carl, Mascouche, CANADA
PA Bristol-Myers Squibb Co., Princeton, NJ, United States (U.S. corporation)
PI US 6713487 B2 20040330
AI US 2002-90288 20020304 (10)
PRAI US 2001-273206P 20010302 (60)
US 2001-273291P 20010302 (60)
DT Utility
FS GRANTED

12/23/04

EXNAM Primary Examiner: Desai, Rita
LREP Winslow, Anastasia P., Rodney, Burton, Duncan, Laurelee A.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **457894-34-7P**
(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-associated disorders)
RN 457894-34-7 USPAT2
CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[(methylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s l41
L52 7 L41

=> s l52 not l51
L53 2 L52 NOT L51

=> d abs bib hitstr 1-2

L53 ANSWER 1 OF 2 USPATFULL on STN
AB The present invention is directed to certain piperidines, pyrrolidines, and hexahydro-1H-azepines of the general structural formula: ##STR1## wherein B is selected from: ##STR2## and R.sup.1, R.sup.1a, R.sup.2a, R.sup.3a, R.sup.3b, R.sup.4, R.sup.4a, R.sup.4b, R.sup.4c, R.sup.5, D, X, Y, n, x and y are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such compounds as the active ingredient thereof are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:108409 USPATFULL
TI Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
IN Chakravarty, Prasun K., Edison, NJ, United States
Chen, Meng H., Westfield, NJ, United States
Nargund, Ravi, East Brunswick, NJ, United States
Patchett, Arthur A., Westfield, NJ, United States
Tata, James R., Westfield, NJ, United States
Wu, Mu Tsu, Clark, NJ, United States
Yang, Lihu, Edison, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5804578 19980908
AI US 1997-828606 19970331 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Ngo, Tamthom T.
LREP Thies, J. Eric, Rose, David L.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2911
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **197900-69-9P 197900-70-2P 197900-71-3P**
197900-72-4P 197900-73-5P 197901-40-9P
197901-41-0P 197901-42-1P 197901-43-2P
197901-44-3P 197901-45-4P
(preparation of tryptophan piperidides and analogs as growth hormone release stimulants)
RN 197900-69-9 USPATFULL
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 197900-70-2 USPATFULL
CN L-Histidinamide, D-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 197900-71-3 USPATFULL
CN L-Histidinamide, D-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 197900-72-4 USPATFULL
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 197900-73-5 USPATFULL
CN L-Histidinamide, L-alanyl-N-[(1R)-1-[[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]carbonyl]-4-phenylbutyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 197901-40-9 USPATFULL
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-41-0 USPATFULL
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[3-[(dimethylamino)carbonyl]-2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-42-1 USPATFULL
CN L-Histidinamide, L-alanyl-N-[(1R)-1-(1H-indol-3-ylmethyl)-2-[3-(5-methyl-1,3,4-oxadiazol-2-yl)-4-phenyl-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-43-2 USPATFULL
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[3-[(ethylamino)carbonyl]-4-phenyl-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-44-3 USPATFULL
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197901-45-4 USPATFULL
CN L-Histidinamide, L-alanyl-N-[(1R)-2-[(3S)-3-[(ethylamino)carbonyl]-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **212773-89-2P**
(preparation of tryptophan piperidides and analogs as growth hormone release stimulants)
RN 212773-89-2 USPATFULL
CN L-Histidinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-N-[(1R)-2-[(3S)-3-(ethoxycarbonyl)-3-(phenylmethyl)-1-piperidinyl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L53 ANSWER 2 OF 2 USPATFULL on STN
AB Compounds of the formula A--B--C--D(--E).sub.p are used to stimulate the release of growth hormone from the pituitary.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:69005 USPATFULL
TI Compounds with growth hormone releasing properties

IN Johansen, Nils Langeland, Copenhagen .O slashed., Denmark
Lau, Jesper, Farum, Denmark
Madsen, Kjeld, V.ae butted.rl.o slashed.se, Denmark
Lundt, Behrend Friedrich, Kokkedal, Denmark
Th.o slashed.gersen, Henning, Farum, Denmark
Hansen, Birgit Sehested, Stenl.o slashed.se, Denmark
Peschke, Bernd, M.ang.l.o slashed.v, Denmark
PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)
PI US 5767085 19980616
WO 9517423 19950629
AI US 1995-448623 19950606 (8)
WO 1994-DK485 19941222
19950606 PCT 371 date
19950606 PCT 102(e) date
PRAI DK 1993-1439 19931223
DK 1994-121 19940128
DK 1994-1191 19941014
DT Utility
FS Granted
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Zelson, Steve T., Lambiris, Elias J.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **170851-25-9P**
(preparation of peptides with growth hormone releasing properties)
RN 170851-25-9 USPATFULL
CN L-Lysinamide, L-alanyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 170851-24-8
CMF C38 H47 N9 O5
CDES 5:L,L,D,D,L

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



=>